18 The Follicular Lymphoma International Prognostic Index (FLIPI) is a commonly used clinical tool that uses 5 factors to assess prognosis for FL: aged >60 years, Ann Arbor stage III to IV ...

PURPOSE: To analyze the outcome of no initial therapy in stage I and II follicular small-cleaved (FSC) and follicular mixed (FM) non-Hodgkin's lymphoma (NHL) on overall survival, time to treatment ...

Follicular lymphoma usually appears as painless, slowly growing lymph nodes. In the early stages of disease there are typically no symptoms, but at advanced stages the patient may experience ...

Patients with follicular lymphoma can often be monitored clinically ... Based on these findings, he undergoes a staging evaluation. PET-CT indicates enlarged hypermetabolic in the cervical ...

Monjuvi, Revlimid, and Rituxan reduced disease progression risk by 57% in relapsed/refractory follicular lymphoma patients compared to placebo plus Revlimid and Rituxan. The investigational regimen ...

Bond and Dr. Sawalha about new data out of ASH in follicular lymphoma. Next, I'd like to discuss the abstract [about] escalating doses of AZD0486, a novel CD19xCD3 T-cell engager. Dr. Sawalha ...

Many types of leukemia produce no obvious symptoms in the early stages. Leukemia red spots are an early warning sign of leukemia. Symptoms of non-Hodgkin's lymphoma may include painless swelling ...

Lunsumio (mosunetuzumab) was approved in the EU as an intravenous treatment for patients with relapsed or refractory follicular lymphoma (FL) in June, becoming the first drug in the class to reach ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

IFLI has a proven track record of advancing lymphoma treatments through strategic funding and collaborative partnerships, including its support for groundbreaking research at Washington University in ...